2019
DOI: 10.3892/or.2019.7130
|View full text |Cite
|
Sign up to set email alerts
|

Heptadecanoic acid inhibits cell proliferation in PC‑9 non‑small‑cell lung cancer cells with acquired gefitinib resistance

Abstract: Non-small cell lung carcinomas (NSCLC) are common and are the leading cause of cancer-associated mortality worldwide. Heptadecanoic acid (C17:0) is an odd-chain saturated fatty acid. The effect of C17:0 on lung cancer has remained elusive. The present study examined the role of C17:0 in the PC-9 NSCLC cell line and PC-9 cells with acquired-gefitinib resistance (PC-9/GR) in vitro. Cell proliferation, migration, apoptosis, fatty acid composition and the activation of relevant signaling pathways were assessed. Th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

2
18
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 22 publications
(20 citation statements)
references
References 37 publications
2
18
0
Order By: Relevance
“…To date, pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0) have been widely utilized as internal standards in gas chromatography experiments, dairy food intake bio-markers, and bio-markers for coronary heart diseases and type II diabetes mellitus [ 25 , 26 , 27 , 28 ]. Interestingly, a recent study demonstrates that heptadecanoic acid (C17:0) can exert anti-cancer effects in gefitinib-resistant non-small cell lung carcinoma (NSCLC) cells, emphasizing the efficacy of OCFAs in targeting human lung cancer cells [ 29 ]. Nevertheless, investigations assessing the anti-cancer effects of odd-chain fatty acids (C15:0 and C17:0) are extremely limited, and no studies have evaluated the in vitro anti-cancer effects of pentadecanoic acid (C15:0).…”
Section: Introductionmentioning
confidence: 99%
“…To date, pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0) have been widely utilized as internal standards in gas chromatography experiments, dairy food intake bio-markers, and bio-markers for coronary heart diseases and type II diabetes mellitus [ 25 , 26 , 27 , 28 ]. Interestingly, a recent study demonstrates that heptadecanoic acid (C17:0) can exert anti-cancer effects in gefitinib-resistant non-small cell lung carcinoma (NSCLC) cells, emphasizing the efficacy of OCFAs in targeting human lung cancer cells [ 29 ]. Nevertheless, investigations assessing the anti-cancer effects of odd-chain fatty acids (C15:0 and C17:0) are extremely limited, and no studies have evaluated the in vitro anti-cancer effects of pentadecanoic acid (C15:0).…”
Section: Introductionmentioning
confidence: 99%
“…Another study found that some OCFAs, such as heptadecanoic acid and omega‐3 polyunsaturated fatty acids, inhibited the proliferation and migration of lung cancer cells by promoting apoptosis and inhibiting the phosphatidylinositol 3‐kinase (PI3K)/Akt signaling pathway [ 61 ]. Heptadecanoic acid was also shown to induce increased apoptosis in lung cancer cells and enhance the cytotoxic effects of gefitinib [ 62 ]. However, the oncogenic mechanism that leads to the production of OCFAs remains unknown.…”
Section: Discussionmentioning
confidence: 99%
“…In addition, some studies have shown that pentadecanoic acid can improve hyperinsulinemia, protect islet cells and improve the inflammatory state of diabetic mice [23]. Heptadecanoic acid is an effective drug against NSCLC cells in vitro [24].…”
Section: Discussionmentioning
confidence: 99%